Indeks matriks metaloproteinaze-9 kao mogući parametar predviđanja akutnog koronarnog sindroma kod dijabetičara
Sažetak
Uvod/Cilj. Indeks matriks metaloproteinaza-9 (MMP-9) predstavlja odnos nivoa aktivne i ukupne MMP-9. On odražava značaj MMP-9 u akutnom koronarnom sindromu (ACS). Metode. Ova studija obuhvatila je tri grupe bolesnika (n = 87): grupa 1 – nedijabetičari bez ACS (kontrola); grupa 2 – dijabetičari sa ACS [podgrupa sa nestabilnom anginom pektoris (UAP), miokardijalnim infarktom (MI) ili reinfarktom]; grupa 3 – nedijabetičari sa ACS. Određivan je nivo ukupne i aktivne MMP-9 da bi se dobio MMP-9 indeks. Rezultati. Index MMP-9, kao marker za ACS, pokazao je dobru senzitivnost i specifičnost za cut off (granične) vrednosti od preko 58.2. Kod dijabetičara MMP-9 bio je viši u ispitivanim grupama nego u kontroli. Index MMP-9 korelisao je sa pojavom ACS i tipom koronarnog događaja. Statistički značajna razlika dobijena je između grupa prema aktivnom MMP-9 (p < 0,001). Isto je nađeno sa aktivnim MMP-9 između kontrolne grupe i grupe sa MI (p < 0,001). Kontrola se visoko statistički značajno razlikovala od grupe bolesnika sa UAP (p < 0,01). Statistički značajne razlike u indeksu MMP-9 nađene su između kontrole i grupe dijabetičara sa ACS (p < 0,001). Statistički značajna razlika nađena je kod MMP-9 indeksa između kontrole u poređenju sa vrednostima kod nedijabetičara sa ACS (p < 0,01). Zaključak. Indeks MMP-9 može biti potencijalni marker za rupturu ateromatoznog plaka kod dijabetičara.
Reference
Cola C, Clementi E, Biondi-Zoccai G, Sangiorgi G. From carotid plaque biology to serologic markers of vulnerability to predict the risk of cerebrovascular events. Acta Chir Belg 2007; 107(2): 129−42.
Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13(3): 333−46.
Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Bi-ol 2007; 8(3): 221−33.
Dabek J, Kulach A, Gasior Z. The role of matrix metalloprotei-nases in acute coronary syndromes. Eur J Int Med 2007; 18(6): 463−6.
Hansson GK. Inflammation, atherosclerosis, and coronary ar-tery disease. N Engl J Med 2005; 352(16): 1685−95.
Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovas-cular disease. Circulation 2003; 107(12): 1579−85.
Newby AC. Do metalloproteinases destabilize vulnerable athe-rosclerotic plaques. Curr Opin Lipidol 2006; 17(5): 556−61.
Tayebjee MH, Lip GY, MacFadyen RJ. Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr Med Chem 2005; 12(8): 917−25.
Kameda K, Matsunaga T, Abe N, Fujiwara T, Hanada H, Fukui K, et al. Increased pericardial fluid level of matrix metalloprotei-nase-9 activity in patients with acute myocardial infarction: possible role in the development of cardiac rupture. Circ J 2006; 70(6): 673−8.
Wagner DR, Delagardelle C, Ernens I, Rouy D, Vaillant M, Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006; 12(1): 66−72.
Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59(4): 812−23.
Tsuzuki M, Morishima I, Yoshida T, Hayashi Y, Miura M, Hirai T, et al. Inverse correlation between soluble CD40 ligand and so-luble CD40 is absent in patients with unstable angina. Heart Vessels 2005; 20(6): 245−50.
Fiotti N, Altamura N, Orlando C, Simi L, Reimers B, Pascotto P, et al Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol 2008; 127(3): 350−7.
American Diabetes Association. Diagnosis and classification of di-abetes mellitus. Diabetes Care 2010; 33(Suppl 1): S62−9.
Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, et al. Modified proenzymes as artifi-cial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity us-ing modified pro-urokinase. Biochem J 1997; 323(3): 603−9.
Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005; 35(6): 331−5.
Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S, et al. Comparison of levels of serum matrix metallo-proteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006; 97(2): 175−80.
Lindsey ML. MMP induction and inhibition in myocardial in-farction. Heart Fail Rev 2004; 9(1): 7−19.
Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of ma-trix metalloproteinases and their inhibitors after myocardial in-farction: a temporal and spatial window. Cardiovasc Res 2006; 69(3): 604−13.
Maekawa K, Tsujino T, Saito K, Kim JI, Ikeda Y, Emoto N, et al. Inhibitory effect of insulin on vasopressin-induced intracellular calcium response is blunted in hyperinsulinemic hypertensive patients: role of membrane fatty acid composition. Heart Ves-sels 2006; 21(4): 205−12.
Aljada A, Ghanim H, Mohanty P, Syed T, Bandyopadhyay A, Dan-dona P. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expres-sion of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am J Clin Nutr 2004; 80(1): 51−7.
Baugh MD, Gavrilovic J, Davies IR, Hughes DA, Sampson MJ. Mo-nocyte matrix metalloproteinase production in Type 2 diabetes and controls - a cross sectional study. Cardiovasc Diabetol 2003; 2: 3.
Gostiljac D, Dorđević PB, Djurić D, Peruničić J, Lasica R, Colak E, et al. The importance of defining serum MMP-9 concentration in diabetics as an early marker of the rupture of atheromatous plaque in acute coronary syndrome. Acta Physiol Hung 2011; 98(1): 91−7.